Sign in
CompletedNo phase

Efficacy and Safety of the New Defocus Spectacle Lens in Preventing Progression of Myopia

Key facts

Who runs it
Zhongshan Ophthalmic Center, Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
174 people enrolled
Started
23 Mar 2023
Ended
22 Apr 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • New defocus spectacle lenses
  • Convenional aspheric single-vision spectacle lenses
Record updated
23 January 2025

Who can take part

Age
6 years to 14 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Aged 6 to 14 years
  • Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -1.00 to -3.50 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.00 D
  • Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen)
  • The intraocular pressure of 10 to 21mmHg
  • Volunteer to participate in this clinical trial with signature of the informed consent form

Who cannot take part

  • Participation of the drug clinical trial within three month and the device clinical trial within one month
  • Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursing products), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc
  • History of eye injury or intraocular surgery
  • Ocular disease, such as uveitis and other inflammatory diseases, glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function
  • Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
  • Clinically abnormal slit-lamp findings
  • Abnormal fundus examination
  • Only one eye meets the inclusion criteria
  • Unable to have regular follow-up

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The clinical effects of new technical spectacles with refractive correction function are mixed. A randomised trial is designed to compare the effects of new defocusing spectacle lenses and traditional aspheric spectacle lenses on myopia progression in Chinese children aged 6-14 years.

The 2 groups in the trial

  • New defocus spectacle lensTreatment being tested

    The children in the experimental group will wear new defocus spectacle lens and receive follow-up examinations every half year.

    Treatment: New defocus spectacle lenses

  • Conventional aspheric single-vision spectacle lensesExisting treatment, for comparison

    The children in the control group will wear conventional aspheric single-vision spectacles and receive follow-up examinations every half year.

    Treatment: Convenional aspheric single-vision spectacle lenses

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of New Defocus Spectacle Lens in Preventing Progression of Myopia Compared With the Conventional Single-vision Spectacle Lens: a Randomized Controlled Trial Among Chinese Children
Record updated
23 January 2025